Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. Journal of clinical anesthesia [J Clin Anesth] Journal article | | Title | Transdermal scopolamine patch in addition to ondansetron for postoperative nausea and vomiting prophylaxis in patients undergoing ambulatory cosmetic surgery. | | Author(s) | Sah N, Ramesh V, Kaul B, Dalby P, Shestak K, Vallejo MC | | Institution | Department of Anesthesiology, Magee Womens Hospital and the University of Pittsburgh, Pittsburgh, PA 15213, USA. sahxnb@anes.upmc.edu | | Source | J Clin Anesth 2009 Jun; 21(4):249-52. | | MeSH | Administration, Cutaneous
Adult
Ambulatory Surgical Procedures
Antiemetics
Cholinergic Antagonists
Double-Blind Method
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Ondansetron
Pain
Postoperative Nausea and Vomiting
Prospective Studies
Scopolamine
Surgery, Plastic
Time Factors
| | Abstract | STUDY OBJECTIVE: To determine the efficacy of transdermal scopolamine in addition to ondansetron in decreasing the incidence of postoperative nausea and vomiting (PONV).
DESIGN: Randomized controlled trial.
SETTING: Academic hospital.
PATIENTS: 126 ASA physical status I and II patients undergoing outpatient plastic surgery with three or more risk factors for PONV.
INTERVENTIONS: Patients were randomly assigned to one of two groups to receive (Group 1) a transdermal scopolamine (TDS) patch or (Group 2), a placebo patch two hours before surgery.
MEASUREMENTS: Occurrence of vomiting, severity of nausea using a visual analog scale (VAS), rescue medication, pain intensity and pain medications, and side effects were recorded every hour until discharge from hospital, then every 4 hours thereafter for a total of 24 hours.
MAIN RESULTS: A statistically significant reduction in postoperative nausea between 8 and 24 hours in patients receiving TDS was noted.
CONCLUSIONS: Transdermal scopolamine in addition to ondansetron benefits patients at high risk for PONV undergoing outpatient plastic surgery for up to 20 hours after surgery. | | Language | eng | | Pub Type(s) | Journal Article
Randomized Controlled Trial
| | PubMed ID | 19502023 |
|
|
| |
Advertise on this site.
| | |
|
